Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	713.84M +391.6%
Revenue (ttm)	389.32M +26.2%
Net Income	129.87M
EPS	0.79
Shares Out	165.24M
PE Ratio	5.48
Forward PE	3.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,720,411
Open	4.320
Previous Close	4.300
Day's Range	4.255 - 4.505
52-Week Range	0.840 - 5.780
Beta	0.21
Analysts	Buy
Price Target	6.10 (+41.2%)
Earnings Date	Aug 6, 2026

About IRWD

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD
• Website: https://ironwoodpharma.com

Financial Performance

In 2025, Ironwood Pharmaceuticals's revenue was $296.15 million, a decrease of -15.72% compared to the previous year's $351.41 million. Earnings were $24.02 million, an increase of 2629.20%.

Analyst Summary

According to 4 analysts, the average rating for IRWD stock is "Buy." The 12-month stock price target is $6.1, which is an increase of 41.20% from the latest price.

Price Target

$6.1

(41.20% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 12, 2026

Data Sources Report a data error